Tegoprazan and Amoxicillin Dual Therapy

Launched by SOONCHUNHYANG UNIVERSITY HOSPITAL · Apr 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for Helicobacter pylori (H. pylori) infections, which are bacteria that can cause stomach problems. The trial is looking at a combination of two medications: tegoprazan, a type of medicine that reduces stomach acid, and amoxicillin, an antibiotic that fights infections. This dual therapy aims to be a more effective option, especially for patients who may not respond well to traditional treatments due to antibiotic resistance. Research has shown that this combination can successfully eliminate the bacteria in about 90% of cases.

To participate in the trial, individuals must be between 20 and 80 years old and eligible for a gastroscopy (a procedure to look at the stomach) and testing for H. pylori. However, those with certain health conditions, severe diseases, or a history of specific treatments for H. pylori may not qualify. Participants will take the medications for 14 days and will be monitored for their response to the treatment. This trial is an exciting opportunity to explore a potentially more effective way to treat H. pylori infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Gastroscopy can be performed
• • H. pylori test and pathological analysis can be performed
• Exclusion Criteria:
• • Age \< 20 or \> 80 years
• • Anemia (serum hemoglobin level \< 10 g/dL)
• • Severe systemic disease
• • Advanced chronic liver disease
• • Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics
• • History of H. pylori eradication
• • Drug allergy to antibiotics
• • History of gastric surgery
• • Recent history of upper gastrointestinal bleeding